Ronald Blue Trust, Inc. Xenon Pharmaceuticals Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.98 Billion
- Q3 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 1,008 shares of XENE stock, worth $42,084. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,008
Previous 367
174.66%
Holding current value
$42,084
Previous $14,000
178.57%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XENE
# of Institutions
211Shares Held
70.2MCall Options Held
37.9KPut Options Held
28.8K-
Avoro Capital Advisors LLC New York, NY5.67MShares$237 Million3.36% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.6MShares$192 Million1.77% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$160 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.71MShares$113 Million3.02% of portfolio
-
Commodore Capital LP New York, NY2.7MShares$113 Million9.03% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.6B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...